TY - JOUR T1 - Validation of NICE diagnostic guidance for rule out of myocardial infarction using high-sensitivity troponin tests JF - Heart JO - Heart SP - 1279 LP - 1286 DO - 10.1136/heartjnl-2016-309270 VL - 102 IS - 16 AU - W A Parsonage AU - C Mueller AU - J H Greenslade AU - K Wildi AU - J Pickering AU - M Than AU - S Aldous AU - J Boeddinghaus AU - C J Hammett AU - T Hawkins AU - T Nestelberger AU - T Reichlin AU - S Reidt AU - M Rubin Gimenez AU - J R Tate AU - R Twerenbold AU - J P Ungerer AU - L Cullen Y1 - 2016/08/15 UR - http://heart.bmj.com/content/102/16/1279.abstract N2 - Objective To validate the National Institute for Health and Care Excellence (NICE) recommended algorithms for high-sensitivity troponin (hsTn) assays in adults presenting with chest pain.Methods International post hoc analysis of three prospective, observational studies from tertiary hospital emergency departments. The primary endpoint was cardiac death or acute myocardial infarction (AMI) within 24 hours of presentation, and the secondary endpoint was major adverse cardiac events (MACE) at 30 days.Results 15% of patients were diagnosed with non-ST elevation myocardial infarction (MI) on admission. The hsTnI algorithm classified 2506/3128 (80.1%) of patients as ‘ruled out’ with 50 (2.0%) missed MI. 943/3128 (30.1%) of patients had a troponin I level below the limit of detection on admission with 2 (0.2%) missed MI. For the hsTnT algorithm, 1794/3374 (53.1%) of patients were ‘ruled out’ with 7 (0.4%) missed MI. 490/3374 (14.5%) of patients had a troponin T below the limit of blank on admission with no MI. MACE at 30 days occurred in 10.7% and 8.5% of patients ‘ruled out’ defined by the hsTnI and hsTnT algorithms, respectively.Conclusions The NICE algorithms could identify patients with low probability of AMI within 2 hours; however, neither strategy performed as predicted by the NICE diagnostic guidance model. Additionally, the rate of MACE at 30 days was sufficiently high that the algorithms should only be used as one component of a more extensive model of risk stratification.Trial registration number ACTRN12611001069943, NCT00470587; post-results. ER -